Comparative Pharmacology
Head-to-head clinical analysis: NORETHIN 1 35E 21 versus NORETHIN 1 50M 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORETHIN 1 35E 21 versus NORETHIN 1 50M 21.
NORETHIN 1/35E-21 vs NORETHIN 1/50M-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release from pituitary, inhibits ovulation, thickens cervical mucus, alters endometrial lining.
Norethindrone is a progestin that suppresses gonadotropin release from the pituitary, inhibiting ovulation. It also induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.
1 tablet orally once daily for 21 days, followed by 7 days off, then repeat. Each tablet contains 1 mg norethindrone acetate and 0.035 mg ethinyl estradiol.
One tablet (norethindrone 1 mg and ethinyl estradiol 50 mcg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Norethindrone: terminal half-life ~7-8 hours (range 5-12 h). Ethinyl estradiol: terminal half-life ~13-27 hours (mean ~17 h). The half-life supports once-daily dosing with stable serum concentrations achieved after 3-5 days.
Terminal elimination half-life: 5-14 hours (mean ~8h). Clinical context: Steady-state achieved after 4-5 days; dosing interval 24 hours maintains therapeutic levels.
Norethindrone and ethinyl estradiol are primarily excreted via urine (approximately 60-80% as metabolites) and feces (about 10-30%). Renal excretion accounts for the majority, with biliary/fecal elimination contributing a minor but significant fraction.
Renal: 50-60% as metabolites; Fecal: 30-40% (via biliary); Less than 5% unchanged in urine.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive